Reference

Oral, quickly disintegrating film, which cannot be spit out, for an antiemetic or antimigraine agent

All Rights Reserved. Oral, quickly disintegrating film, which cannot be spit out, for an antiemetic or antimigraine agent. Obermeier, Petra; Kohr, Thomas; Kramer, Kai-Thomas; Klokkers, Karin (Hexal A.-G., Germany). PCT Int. Appl.Some commonly used reagents like 102670-46-2 and 154323-57-6 are used in this experiment. WO 2007009800 A2 25 Jan 2007, 24pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-EP7176 20 Jul 2006. PRIORITY: DE 2005-102005033942 20 Jul 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) The invention relates to a film-shaped, single-layered and cavity-free prepn. that does not contain any surfactants nor effervescent additives and flavor masking agents, comprised of film forming agents, one or more gelling agents and of one or more active substances selected from the group of antiemetics and antimigraine agents. Thus a film included (wt./wt.%): naratriptan 50; hydroxypropylmethylcellulose 30; ethylcellulose 5; paraffin oil 5; D-sorbitol 5; 1,3-butane diol 2.5; iso-Pr palmitate 2.5. .

Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks

All Rights Reserved. Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. Massiou, Helene; Pradalier, Andre; Donnet, Anne; Lanteri-Minet, Michel; Allaf, Bashar (Service de Neurologie, Hopital Lariboisiere, Paris FR-75475, Fr.). European Neurology, 55(4), 198-203 (English) 2006 S. Karger AG. CODEN: EUNEAP. ISSN: 0014-3022.Chemical with cas number 154323-57-6 also plays role. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The objective of the open-label, multicenter Migraine - Satisfaction with Treatment: Reality with Almogran study was to assess efficacy, tolerability, and satisfaction with almotriptan 12.5 mg among migraineurs who were not achieving adequate results with their current acute therapy. Data from 434 patients (342 evaluable), were obtained for 929 attacks by 154 neurologists in France. Using a questionnaire developed by the National Agency for Accreditation and Evaluation in Health (ANAES), almotriptan was assocd. with an increased proportion of patients experiencing significant relief at 2 h (69.3 vs. 26.6%), tolerating the medication well (91.2 vs. 76.0%), able to resume activities (70.5 vs. 24.9%), and taking only 1 dose (59.4 vs. 28.1%) compared with previous therapies. At 2 h, headache pain had disappeared in 33.4% of attacks and was mild in 26.9%. Recurrence rate was 28.4% and rescue analgesics were used in 20.9% of attacks. The rate of adverse event-related discontinuations was 2.6%. The proportion of patients who were very satisfied/satisfied overall with almotriptan treatment was 69%. Almotriptan 12.5 mg was effective, well-tolerated and assocd. with a high rate of treatment satisfaction in patients whose previous acute migraine therapy was inadequate according to the ANAES recommendations. .